Xalkori And Inlyta: NICE Pans Two Pfizer Oncology Drugs In Two Days
Britain’s NICE has rejected Pfizer’s Xalkori (crizotinib) for lung cancer and Inlyta (axitinib) for kidney carcinoma within two days of each other, putting drug discounts back in the spotlight.